GLP-1 Newsroom is your go-to source for breaking news, expert updates, trends, products, and real-world insights on everything related to GLP-1 medications, journeys, and diets.
GLP-1 medications are poised to be a $125 billion industry by 2030, and that has a lot of people wondering how to get the same boost you can get in drugs like Ozempic and Zepbound naturally.
The rapid rise of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has transformed obesity and diabetes care. Yet, as more people use these medications, a common experience emerges: the GLP-1 weight loss plateau.
